TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34915900

Group type: EXPERIMENTAL
Intervention: Text messaging combined with a pedometer; motivational messages to encourage walking and accountability messages to report pedometer steps.
Number of subjects: 44
Study: 34915905

Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE)
Number of subjects: 20
Study: 34915909

Group type: EXPERIMENTAL
Intervention: Internet-delivered modular intervention based on cognitive behavioral therapy (CBT) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control for 8 weeks, followed by access to the intervention for 8 weeks
Number of subjects: 60
Study: 34915924

Group type: EXPERIMENTAL
Intervention: Lactation Counseling for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine education in prenatal care and prenatal and childbirth classes
Number of subjects: 0
Study: 34915984

Group type: EXPERIMENTAL
Intervention: Presence of Coandă effect
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Presence of flail leaflet
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Presence of both Coandă effect and flail leaflet
Number of subjects: 158

Group type: COMPARATOR
Intervention: No Coandă or flail
Number of subjects: 158

Group type: COMPARATOR
Intervention: Coandă effect only
Number of subjects: 158

Group type: COMPARATOR
Intervention: Flail leaflet only
Number of subjects: 158

Group type: COMPARATOR
Intervention: Both Coandă effect and flail leaflet
Number of subjects: 158
Study: 34916316

Group type: EXPERIMENTAL
Intervention: Community-based research study ANRS Trans&HIV
Number of subjects: 0
Study: 34916319

Group type: EXPERIMENTAL
Intervention: Transition to adult mental health services (AMHS)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Self-reported problems
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Clinician ratings of illness severity
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Psychotropic medication use
Number of subjects: 763
Study: 34916324

Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty (BT)
Number of subjects: 157
Study: 34916326

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PLWH
Number of subjects: 400
Study: 34916327

Group type: EXPERIMENTAL
Intervention: Perioperative intravenous S(+)-ketamine plus conventional anaesthesia
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Conventional anaesthesia only
Number of subjects: 12000
Study: 34916627

Group type: EXPERIMENTAL
Intervention: Outpatient dietary counseling
Number of subjects: 90
Study: 34916740

Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation (MV)
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Vasopressors or Inotropes (VIs)
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: ICU Mortality
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Compliance for process measures related to MV
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Monitoring delirium, sedation, and analgesia
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Inappropriate transfusion of blood products
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Use of capnography
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Predictors of mortality
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Hospital size and closed ICUs
Number of subjects: 4669

Group type: EXPERIMENTAL
Intervention: Terminal Discharges (TDs)
Number of subjects: 4669
Study: 34917079

Group type: EXPERIMENTAL
Intervention: Early myeloid-derived suppressor cells (eMDSCs) frequencies in engrafted patients at PT-Day 30
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High donor myeloid chimerism (HDMC) group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of eMDSCs and Tregs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokines associated with engraftment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixed chimeric eMDSCs and cytokines
Number of subjects: 20
Study: 34917174

Group type: EXPERIMENTAL
Intervention: Veliparib plus carboplatin/paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34917565

Group type: EXPERIMENTAL
Intervention: High-dose gentamicin regimen
Number of subjects: 0
Study: 34917636

Group type: EXPERIMENTAL
Intervention: Implantation of microalgae (photosynthetic cells) for oxygen supply to tissues, specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 34918337

Group type: COMPARATOR
Intervention: Typical antipsychotics (e.g. haloperidol, thiothixene)
Number of subjects: 6090

Group type: COMPARATOR
Intervention: Atypical antipsychotics (e.g. risperidone, olanzapine, aripiprazole, quetiapine)
Number of subjects: 6090
Study: 34918546

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 0
Study: 34918545

Group type: EXPERIMENTAL
Intervention: Tepotinib plus osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34918624

Group type: EXPERIMENTAL
Intervention: Tendyne valve (TMVR)
Number of subjects: 20
Study: 34918637

Group type: EXPERIMENTAL
Intervention: Single acupoint group (Shenmen HT7)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Compatibility acupoint group (Shenmen HT7, Baihui DU20, Sanyinjiao SP6)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Nonacupoint control group
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 333
Study: 34918855

Group type: EXPERIMENTAL
Intervention: Diabetes (HbA1c ≥6.5% or history of diabetes)
Number of subjects: 4796

Group type: EXPERIMENTAL
Intervention: Pre-diabetes (HbA1c 6.0%-6.4%)
Number of subjects: 4796

Group type: EXPERIMENTAL
Intervention: Diabetes treated with insulin
Number of subjects: 4796

Group type: EXPERIMENTAL
Intervention: Lean diabetes
Number of subjects: 4796

Group type: COMPARATOR
Intervention: Normal HbA1c (<6.0%)
Number of subjects: 4796
Study: 34919824

Group type: EXPERIMENTAL
Intervention: Sotorasib, oral administration once per day
Number of subjects: 62
Study: 34920345

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neither SXB nor stimulants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sodium oxybate (SXB) with or without stimulants
Number of subjects: 100
Study: 34920728

Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-septic patients
Number of subjects: 2
Study: 34920739

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Weight loss with Metformin
Number of subjects: 192

Group type: COMPARATOR
Intervention: Weight loss with Placebo
Number of subjects: 192
Study: 34920917

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily
Number of subjects: 25
Study: 34920946

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 18
Study: 34921021

Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1)
Number of subjects: 147
Study: 34921052

Group type: EXPERIMENTAL
Intervention: Postoperative plasma levels of cytokines (IL-10, IL-1β, vascular endothelial growth factor, IL12/IL23p40)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Prearthrotomy synovial fluid IL-10 levels
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Incidence of persistent pain at 6 months post TKA
Number of subjects: 162
Study: 34921084

Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 48,000 IU vitamin D
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (24,000 IU, 48,000 IU, and placebo)
Number of subjects: 45
Study: 34921238

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 98
Study: 34921324

Group type: EXPERIMENTAL
Intervention: Rapid 5-mL/kg body weight volume expansion
Number of subjects: 38
Study: 34921355

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4581
Study: 34921514

Group type: EXPERIMENTAL
Intervention: Romiplostim 1 μg/kg weekly for 2 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Romiplostim 3 μg/kg weekly for 2 weeks
Number of subjects: 16
Study: 34921665

Group type: EXPERIMENTAL
Intervention: Vibegron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34921668

Group type: EXPERIMENTAL
Intervention: Digitally supported cognitive interviewing using telephone and videoconferencing
Number of subjects: 0
Study: 34921669

Group type: EXPERIMENTAL
Intervention: Risankizumab (RISA) only
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Placebo followed by Risankizumab (PBO/RISA)
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Ustekinumab (UST) only
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Adalimumab (ADA) followed by re-randomization to ADA or RISA (ADA and ADA/RISA)
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Risankizumab followed by re-randomization to Risankizumab or placebo (RISA and RISA/PBO)
Number of subjects: 2101
Study: 34921845

Group type: EXPERIMENTAL
Intervention: Nivolumab (added in vitro)
Number of subjects: 21

Group type: COMPARATOR
Intervention: PBMCs of IC patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: PBMCs of controls (healthy and cancer patients)
Number of subjects: 21
Study: 34922192

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched products
Number of subjects: 7223

Group type: EXPERIMENTAL
Intervention: Lifestyle measures to lower cholesterol
Number of subjects: 7223

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 7223

Group type: EXPERIMENTAL
Intervention: Reducing dietary fat
Number of subjects: 7223

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 7223
Study: 34922392

Group type: EXPERIMENTAL
Intervention: Acculturative stress (measured using a 9-item scale)
Number of subjects: 400
Study: 34922530

Group type: EXPERIMENTAL
Intervention: Patient-Centered Survivorship Care Index (PC-SCI)
Number of subjects: 1278
Study: 34922610

Group type: EXPERIMENTAL
Intervention: Prone position ventilation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study: 34922608

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention delivered by trained community health workers over 12 months (5 one-on-one sessions, 4 group sessions, 13 telephone sessions).
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Usual care comprising a single 30-min session of lifestyle modification advice from the community health worker.
Number of subjects: 3600
Study: 34922614

Group type: EXPERIMENTAL
Intervention: DBS-based, drug resistance genotype-informed ART switching algorithm
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Follow-up VL testing
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Genotypic testing
Number of subjects: 152
Study: 34922616

Group type: EXPERIMENTAL
Intervention: SmartFeeding4Kids (SF4K) program, an online self-guided 7-session intervention for parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34922648

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34922860

Group type: EXPERIMENTAL
Intervention: Active AL amyloidosis
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Remission AL amyloidosis
Number of subjects: 69

Group type: COMPARATOR
Intervention: Comparison of myocardial ECV between active and remission groups
Number of subjects: 69
Study: 34922871

Group type: EXPERIMENTAL
Intervention: Transcatheter intervention for severe aortic stenosis
Number of subjects: 0
Study: 34923853

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous CD34+ cell therapy
Number of subjects: 20
Study: 34923905

Group type: EXPERIMENTAL
Intervention: Inulin supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 34923911

Group type: EXPERIMENTAL
Intervention: Long-chain inulin+resistant starch (INU+RS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta glucan+resistant starch (BG+RS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta glucan (BG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maltodextrin (PLA)
Number of subjects: 0
Study: 34924020

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Matching placebo (Ringer's lactate)
Number of subjects: 90
Study: 34924031

Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 25

Group type: COMPARATOR
Intervention: IVIM-DWI
Number of subjects: 25
Study: 34924034

Group type: EXPERIMENTAL
Intervention: Web-based patient education delivered through an e-learning programme at home
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard face-to-face patient education provided at the hospital
Number of subjects: 200
Study: 34924145

Group type: EXPERIMENTAL
Intervention: entrectinib
Number of subjects: 0
Study: 34925094

Group type: EXPERIMENTAL
Intervention: NDBI program augmented with Video Feedback (VF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early Intervention (EI) NDBI program
Number of subjects: 0
Study: 34925157

Group type: EXPERIMENTAL
Intervention: Online transdiagnostic intervention with self-enhancement strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online transdiagnostic intervention without self-enhancement strategies (control)
Number of subjects: 0
Study: 34925553

Group type: EXPERIMENTAL
Intervention: DHP107 (oral paclitaxel) 200 mg/m²
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study: 34926296

Group type: EXPERIMENTAL
Intervention: Tcm self-transfusion combined with TACE treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: TACE treatment alone (control group)
Number of subjects: 48
Study: 34926300

Group type: EXPERIMENTAL
Intervention: TACE combined with endoscopic therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: TACE only (control group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Primary prophylaxis
Number of subjects: 89

Group type: COMPARATOR
Intervention: Secondary prophylaxis
Number of subjects: 89
Study: 34926386

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatments
Number of subjects: 0
Study: 34926496

Group type: EXPERIMENTAL
Intervention: Hyponatremia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammation at admission
Number of subjects: 0
Study: 34926573

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34926601

Group type: EXPERIMENTAL
Intervention: Shenfu Injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34926604

Group type: EXPERIMENTAL
Intervention: Disproportionate Mitral Regurgitation
Number of subjects: 0
Study: 34926707

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 160
Study: 34926839

Group type: EXPERIMENTAL
Intervention: Stereotactic Brain Irradiation (SBI) by LINAC with monoisocentric technique and non-coplanar arcs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Whole Brain Irradiation (WBI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stereotactic Brain Irradiation (SBI)
Number of subjects: 100
Study: 34926859

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 110-149 mg/dl
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 150-180 mg/dl
Number of subjects: 144
Study: 34927159

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34927165

Group type: EXPERIMENTAL
Intervention: Telehealth physical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person physical therapy
Number of subjects: 0
Study: 34927192

Group type: EXPERIMENTAL
Intervention: Pre-pandemic measures
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Peri-pandemic measures
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Patients who had COVID-19
Number of subjects: 716
Study: 34927307

Group type: EXPERIMENTAL
Intervention: Earlier locally ablative treatment of oligometastases
Number of subjects: 42
Study: 34927477

Group type: EXPERIMENTAL
Intervention: Psychological and physical intimate partner violence (IPV) from female partners to male partners
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Psychological and physical intimate partner violence (IPV) from male partners to female partners
Number of subjects: 713
Study: 34927526

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study: 34927561

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 562

Group type: COMPARATOR
Intervention: No-added iron
Number of subjects: 562
Study: 34927594

Group type: EXPERIMENTAL
Intervention: ASCENSO online platform (intervention group)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) (control group)
Number of subjects: 167
Study: 34927596

Group type: EXPERIMENTAL
Intervention: Health education intervention on diabetic retinopathy (DR) provided to health personnel using IEC materials (PowerPoint presentations, posters, pamphlets, videos, pre- and postevaluation questionnaires, referral slip).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education intervention on diabetic retinopathy (DR).
Number of subjects: 0
Study: 34928237

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention using a neuroscience-based approach to mindfulness (Healthy Minds Program - HMP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study: 34928249

Group type: EXPERIMENTAL
Intervention: Multilevel intervention for HPV vaccination (Development of Systems and Education for Human Papillomavirus Vaccination)
Number of subjects: 0
Study: 34928316

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34928481

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 62
Study: 34928491

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 0
Study: 34928709

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 2 doses, followed by computed tomography scan at week 6.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 3rd and 4th doses if no FATE at week 6, followed by Nivolumab monotherapy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nivolumab + Ipilimumab (standard treatment)
Number of subjects: 60
Study: 34928871

Group type: EXPERIMENTAL
Intervention: Kangaroo care and sucrose for infant pain control
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 236
Study: 34929010

Group type: EXPERIMENTAL
Intervention: Healthcare-associated encounters among patients in a Center
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental isolates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characterization of potential transmission modes and settings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence and prevalence of healthcare-associated environmental NTM species/subspecies
Number of subjects: 0
Study: 34929034

Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 567

Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Participants with incident SARS-CoV-2 infection
Number of subjects: 567
Study: 34930015

Group type: EXPERIMENTAL
Intervention: Melody transcatheter pulmonary valve (TPV) replacement
Number of subjects: 171
Study: 34930020

Group type: EXPERIMENTAL
Intervention: Genome sequencing for Mendelian arrhythmia genes
Number of subjects: 21846

Group type: EXPERIMENTAL
Intervention: Return of variant results
Number of subjects: 21846

Group type: EXPERIMENTAL
Intervention: In vitro functional evaluation of 50 variants of uncertain significance
Number of subjects: 21846
Study: 34930139

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) at 5 min after intubation (DS5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) from DS5 to OLV30
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) at DS5, DL5, and OLV10
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) at DS5
Number of subjects: 50
Study: 34930140

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 96 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Entecavir (ETV) 0.5 mg once daily
Number of subjects: 75
Study: 34930165

Group type: EXPERIMENTAL
Intervention: BRCA1/BRCA2 somatic PSVs testing via next-generation sequencing (NGS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Debulking surgery
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Germline PSVs tests for patients with BRCA1/BRCA2 somatic PSVs
Number of subjects: 105
Study: 34930172

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy for primary breast cancer
Number of subjects: 51
Study: 34930182

Group type: EXPERIMENTAL
Intervention: Quality Improvement Package (QIP) including a designated viral load champion, technological enhancement of TIER.Net, and a dashboard system.
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Quality Improvement Package (QIP)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Current care (control)
Number of subjects: 750
Study: 34930194

Group type: EXPERIMENTAL
Intervention: Exercise therapy + internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Exercise therapy + iCBT in combination with TKA
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual treatment with TKA and usual care physiotherapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Exercise therapy + iCBT
Number of subjects: 282